Anna Binyamin

Anna Binyamin

Auto-generated profile, based on publicly available information

Anna Binyamin

Immunology Program, Sloan Kettering Institute, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AAAnthony C. Antonelli
Anthony C. Antonelli
ABAnna Binyamin
Anna Binyamin
THTobias M. Hohl
Tobias M. Hohl
MGMichael S. Glickman
Michael S. Glickman
GRGil Redelman-Sidi
Gil Redelman-Sidi
Significance: Bacillus Calmette–Guérin (BCG) therapy is one of the oldest tumor immunotherapies, but its mechanism remains unknown. Herein we show that BCG therapy induces tumor-specific T cell-dependent immunity that is predominantly mediated by CD4 T cells in a manner distinct from other tumor immunotherapies. These immunologic insights may allow investigation into biomarkers that could predict the efficacy of BCG in human cancer patients.

30 August 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
For decades, BCG immunotherapy has been the standard of care for non–muscle-invasive bladder cancer. Despite this clinical experience, the mechanism by which BCG stimulates tumor-eliminating immunity is unclear, and there is still a need for more accurate prediction of clinical outcomes in advance of treatment initiation. We have shown that BCG stimulates tumor-specific T-cell immunity that requires tumor cell expression of the IFNγ receptor (IFNGR); however, the downstream components of IFNGR signaling responsible for responsiveness to BCG are unknown. Here, we demonstrate that the IFNγ-driven, tumor cell intrinsic expression of the class II transactivator CIITA is required for activation of a tumor-specific CD4 T-cell response and BCG-induced tumor immunity. Despite the established role for CIITA in controlling MHC-II antigen presentation machinery, the requirement for CIITA is independent of MHC-II and associated genes. Rather, we find that CIITA is required for a broader tumor-intrinsic transcriptional program linked to critical pathways of tumor immunity via mechanisms that remain to be determined. Tumor cell intrinsic expression of CIITA is not required for a response to immunotherapy targeting programmed cell death protein 1 (PD-1), suggesting that different modalities of immunotherapy for bladder cancer could be employed based on tumor-intrinsic characteristics.

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II

4 April 2023
Verified
Other
Open access
GRGil Redelman-Sidi
Gil Redelman-Sidi
ABAnna Binyamin
Anna Binyamin
AAAnthony C. Antonelli
Anthony C. Antonelli
WCWill Catalano
Will Catalano
JBJames Bean
James Bean
MGMichael S. Glickman
Michael S. Glickman
Supplementary Figure from BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II